Stock listing
NASDAQ:BEAM Beam Therapeutics Inc. Stock
Home listing (NASDAQ) of Beam Therapeutics Inc.
Follow Beam Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BEAM
$20.90 USD -0.11 (-0.5%)
Close on Nov 20, 2026
- Day range
- $20.54 – $22.10 USDNov 20, 2026
- Volume
- 3.88M sharesNov 20, 2026
- Market cap
- $2.16B USDAt the close on Nov 20, 2026 · price × 103.5M shares outstanding
- 52-week range
- $20.39 – $38.26 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $51.21M USDMedian day 1.67M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BEAM · Home | $20.90 USD | -0.11 (-0.5%) | 3,882,474 | $20.54 | $22.10 | $20.54 | $21.01 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BEAM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $20.90 | -0.11 | -0.5% | $20.54 | $22.10 | $20.54 | 3,882,474 | |
| $21.01 | +0.36 | +1.7% | $20.76 | $22.40 | $20.66 | 4,863,844 | |
| $20.65 | -0.29 | -1.4% | $20.83 | $22.05 | $20.54 | 4,125,398 | |
| $20.94 | -1.89 | -8.3% | $22.43 | $22.70 | $20.65 | 3,316,371 | |
| $22.83 | -1.20 | -5.0% | $24.03 | $24.06 | $22.81 | 2,044,828 | |
| $24.03 | -1.78 | -6.9% | $25.06 | $25.15 | $23.86 | 1,506,295 | |
| $25.81 | +0.66 | +2.6% | $25.47 | $26.07 | $24.68 | 1,582,833 | |
| $25.15 | -1.87 | -6.9% | $26.45 | $27.00 | $23.60 | 3,115,526 | |
| $27.02 | +0.61 | +2.3% | $26.79 | $27.39 | $25.96 | 1,288,080 | |
| $26.41 | +0.54 | +2.1% | $26.07 | $26.75 | $25.86 | 1,982,824 | |
| $25.87 | -1.92 | -6.9% | $27.37 | $27.48 | $24.88 | 2,988,339 | |
| $27.79 | +1.46 | +5.5% | $27.06 | $28.00 | $26.26 | 1,347,633 | |
| $26.33 | +0.46 | +1.8% | $26.26 | $27.20 | $25.99 | 1,427,309 | |
| $25.87 | -1.36 | -5.0% | $27.45 | $27.67 | $25.79 | 1,439,270 | |
| $27.23 | -1.61 | -5.6% | $28.27 | $28.80 | $26.43 | 1,497,886 | |
| $28.84 | +0.06 | +0.2% | $28.72 | $29.76 | $28.40 | 1,995,700 | |
| $28.78 | +3.88 | +15.6% | $24.61 | $28.86 | $24.50 | 5,003,200 | |
| $24.90 | +1.11 | +4.7% | $23.73 | $25.09 | $23.39 | 2,750,600 | |
| $23.79 | -0.26 | -1.1% | $24.00 | $24.11 | $23.65 | 1,400,500 | |
| $24.05 | -0.51 | -2.1% | $24.00 | $24.14 | $23.24 | 1,596,100 | |
| $24.56 | -0.28 | -1.1% | $24.39 | $25.29 | $24.00 | 1,383,600 | |
| $24.84 | -0.09 | -0.4% | $24.83 | $25.20 | $24.50 | 1,167,700 | |
| $24.93 | +0.74 | +3.1% | $24.00 | $25.06 | $23.61 | 1,479,500 | |
| $24.19 | +0.72 | +3.1% | $23.89 | $24.38 | $23.50 | 1,316,500 | |
| $23.47 | -1.26 | -5.1% | $24.56 | $24.56 | $23.16 | 1,645,800 | |
| $24.73 | +1.08 | +4.6% | $23.51 | $24.98 | $23.20 | 1,779,900 | |
| $23.65 | -0.78 | -3.2% | $24.13 | $24.26 | $23.28 | 1,660,700 | |
| $24.43 | -0.70 | -2.8% | $24.88 | $24.93 | $24.08 | 1,667,900 | |
| $25.13 | -0.57 | -2.2% | $25.63 | $26.09 | $24.94 | 1,412,800 | |
| $25.70 | +1.10 | +4.5% | $24.72 | $26.23 | $24.55 | 1,800,200 | |
| $24.60 | -0.17 | -0.7% | $24.26 | $24.69 | $23.91 | 2,425,900 | |
| $24.77 | -0.46 | -1.8% | $24.64 | $25.37 | $24.45 | 2,342,400 | |
| $25.23 | -0.44 | -1.7% | $26.80 | $26.94 | $24.87 | 2,516,700 | |
| $25.67 | +1.17 | +4.8% | $24.48 | $26.04 | $23.83 | 1,999,200 | |
| $24.50 | +0.11 | +0.5% | $25.00 | $25.48 | $24.21 | 1,497,500 | |
| $24.39 | -0.06 | -0.2% | $24.24 | $24.98 | $23.96 | 1,693,300 | |
| $24.45 | -0.07 | -0.3% | $24.79 | $25.20 | $24.41 | 1,555,600 | |
| $24.52 | +0.29 | +1.2% | $23.88 | $24.76 | $23.88 | 1,637,100 | |
| $24.23 | -0.04 | -0.2% | $24.02 | $24.66 | $23.44 | 1,273,600 | |
| $24.27 | -0.39 | -1.6% | $24.97 | $24.97 | $23.75 | 1,217,900 | |
| $24.66 | +0.29 | +1.2% | $23.88 | $24.81 | $23.16 | 2,283,000 | |
| $24.37 | -1.56 | -6.0% | $25.75 | $26.24 | $24.22 | 1,896,000 | |
| $25.93 | +0.67 | +2.7% | $25.62 | $26.50 | $25.07 | 1,987,800 | |
| $25.26 | +0.31 | +1.2% | $25.45 | $25.66 | $24.83 | 1,701,300 | |
| $24.95 | +0.28 | +1.1% | $24.92 | $25.18 | $24.26 | 2,286,600 | |
| $24.67 | +1.57 | +6.8% | $24.28 | $25.50 | $24.05 | 2,424,400 | |
| $23.10 | -0.12 | -0.5% | $23.41 | $23.65 | $22.67 | 1,817,700 | |
| $23.22 | -0.90 | -3.7% | $23.82 | $23.84 | $22.86 | 2,584,100 | |
| $24.12 | +0.13 | +0.5% | $24.02 | $24.93 | $23.99 | 1,457,100 | |
| $23.99 | -0.38 | -1.6% | $24.64 | $24.76 | $23.95 | 1,193,700 | |
| $24.37 | -0.805 | -3.2% | $24.76 | $24.89 | $23.98 | 1,980,300 | |
| $25.18 | -1.655 | -6.2% | $26.70 | $26.70 | $25.11 | 2,842,800 | |
| $26.83 | -2.83 | -9.5% | $26.76 | $27.30 | $25.04 | 6,174,900 | |
| $29.66 | +0.20 | +0.7% | $28.91 | $29.97 | $28.91 | 1,181,600 | |
| $29.46 | +0.17 | +0.6% | $29.49 | $29.65 | $28.02 | 1,266,600 | |
| $29.29 | +0.27 | +0.9% | $29.27 | $30.18 | $28.23 | 1,292,200 | |
| $29.02 | -0.41 | -1.4% | $28.82 | $29.56 | $28.70 | 887,900 | |
| $29.43 | +0.11 | +0.4% | $28.82 | $29.82 | $28.33 | 1,308,000 | |
| $29.32 | -1.16 | -3.8% | $29.53 | $30.50 | $29.01 | 1,330,100 | |
| $30.48 | +0.29 | +1.0% | $30.14 | $30.82 | $29.72 | 1,268,800 | |
| $30.19 | -0.84 | -2.7% | $30.96 | $31.02 | $29.76 | 1,386,700 | |
| $31.03 | +2.70 | +9.5% | $28.94 | $31.48 | $28.78 | 2,188,665 | |
| $28.33 | -1.43 | -4.8% | $29.25 | $29.35 | $28.23 | 1,245,306 | |
| $29.76 | +1.37 | +4.8% | $28.74 | $30.50 | $28.61 | 2,457,300 | |
| $28.39 | -0.68 | -2.3% | $28.08 | $29.10 | $26.98 | 2,409,500 |
- Ticker
- NASDAQ:BEAM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Latest earnings call · Feb 24, 2026
Beam Therapeutics (NASDAQ:BEAM) Q4 2025 Earnings Call
Replay and transcript
Latest deck · September 2026
European Respiratory Society (ERS) Congress 2026
Conference · 9 slides
Latest news
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Nov 10, 2026
Closed $25.15 (-6.9%) on Nov 10, 2026
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Nov 4, 2026
Closed $27.79 (+5.5%) on Nov 4, 2026
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Nov 3, 2026
Closed $26.33 (+1.8%) on Nov 3, 2026
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
Oct 27, 2026
Closed $24.90 (+4.7%) on Oct 27, 2026
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
Sep 8, 2026
Closed $26.83 (-9.5%) on Sep 8, 2026
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Sep 1, 2026
Closed $29.02 (-1.4%) on Sep 1, 2026
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Aug 31, 2026
Closed $29.43 (+0.4%) on Aug 31, 2026
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Aug 4, 2026
Closed $28.35 (+9.4%) on Aug 4, 2026
Beam Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 160 in all · newest Nov 10, 2026 · oldest 2020
- Calls
- 2 calls with a replay · 2 with a transcript · latest Feb 24, 2026
- Decks
- 16 decks · latest September 2026
Where Beam Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BEAM · Home listing · This page | NASDAQ | United States | USD |
| BMV:BEAM | BMV | Mexico | MXN |
| BOATS:BEAM | BOATS | United States | USD |
| BIVA:BEAM | BIVA | Mexico | MXN |
Valuation
EV/sales 8.3× against a median of 18.8×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.22B USD
- P/E
- Loss
- EV/sales
- 8.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.3×
- Gross margin
- 100.0%
- Operating margin
- −267.7%
- Net margin
- −73.9%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.90
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc. · NASDAQ:BEAM | US$2.16B | US$1.22B | n/a | 8.3× | n/a | 2.3× | −73.9% | 0.1× | 1.90 |
| InSilico Medicine Cayman TopCo · HKEX:3696 | US$2.29B | US$1.70B | n/a | 30.3× | n/a | 4.2× | −626.5% | 0.0× | n/a |
| Arcus Biosciences, Inc. · NYSE:RCUS | US$2.25B | US$1.72B | n/a | 17.2× | n/a | 6.3× | −453.0% | 0.3× | 1.37 |
| SK bioscience Co.,Ltd. · KRX:302440 | US$2.24B | US$2.02B | n/a | 4.1× | n/a | 1.7× | −12.8% | 0.3× | n/a |
| NewAmsterdam Pharma Company N.V. · NASDAQ:NAMS | US$2.20B | US$1.57B | n/a | 60.6× | n/a | 3.5× | −789.9% | 0.0× | 1.41 |
| Lakefront Biotherapeutics · EURONEXT:LKFT | US$2.20B | −US$260.7M | 3.4× | −0.2× | n/a | 0.6× | 60.2% | 0.0× | n/a |
| Pharvaris N.V. · NASDAQ:PHVS | US$2.20B | US$1.89B | n/a | n/a | n/a | 7.5× | n/a | 0.0× | 0.76 |
| BioArctic AB Class B · OMXSTO:BIOA_B | US$2.19B | US$2.00B | 212× | 20.4× | 90.0× | 11.1× | 10.5% | 0.0× | n/a |
| Celldex Therapeutics, Inc. · NASDAQ:CLDX | US$2.15B | US$1.50B | n/a | n/a | n/a | 3.3× | n/a | 0.0× | 1.07 |
| Palvella Therapeutics, Inc. · NASDAQ:PVLA | US$2.09B | US$1.85B | n/a | n/a | n/a | 10.6× | n/a | 0.0× | 1.50 |
| Regencell Bioscience Holdings Limited · NASDAQ:RGC | US$2.07B | US$2.06B | n/a | n/a | n/a | 155× | n/a | 0.0× | 1.57 |
| Median of the others | US$2.20B | US$1.79B | 108× | 18.8× | 90.0× | 5.2× | −232.9% | 0.0× | 1.39 |
Forecasts
12 strong buy · 1 buy · 2 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 49.85 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.55 · 15 analysts
- Revenue, year to Dec 2026
- 38.48M · 13 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| John Evans | Chief Executive Officer and Board Member |
| Sravan Emany | Chief Financial Officer |
| Giuseppe Ciaramella | President |
| Christine Bellon | Chief Legal Officer |
| Bethany Cavanagh | Senior Vice President of Finance, Treasurer and Principal Accounting Officer |
| Amy Simon | Chief Medical Officer |
| Eric Foster | Chief Commercial Officer |
| Gopi Shanker | Chief Scientific Officer |
| Manmohan Singh | Chief Technology Officer |
| Susan O’Connor | Chief Human Resources Officer |
Board
| Director | Role |
|---|---|
| Chirfi Guindo | Board Member |
| Christi Shaw | Board Member |
| Graham Cooper | Board Member |
| John Evans | Chief Executive Officer and Board Member |
| John Maraganore | Board Member |
| Kate Walsh | Board Member |
| Mark Fishman | Independent Lead Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Beam Therapeutics (NASDAQ:BEAM) Q4 2025 Earnings Call | Tue, Feb 24, 2026 · 8:00 AM ET | Replay |
| Beam Therapeutics (NASDAQ:BEAM) Q3 2024 Earnings Call | Tue, Nov 05, 2024 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 3, 2026 · Before open | +1.8% |
| Q2 2026 | Aug 4, 2026 · Before open | +9.4% |
| Q1 2026 | May 7, 2026 · Before open | −2.7% |
| Q4 2025 | Feb 24, 2026 | +4.5% |
| Q3 2025 | Nov 4, 2025 · Before open | −6.2% |
| Q2 2025 | Aug 5, 2025 · Before open | −2.2% |
| Q1 2025 | May 6, 2025 · Before open | −19.3% |
| Q4 2024 | Feb 25, 2025 · Before open | −3.1% |
| Q3 2024 | Nov 5, 2024 · Before open | −1.8% |
| Q2 2024 | Aug 6, 2024 · Before open | −0.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | −1.1% |
| Q4 2023 | Feb 27, 2024 · Before open | +25.9% |
| Q3 2023 | Nov 8, 2023 · Before open | −8.4% |
| Q2 2023 | Aug 8, 2023 · Before open | +2.8% |
| Q1 2023 | May 10, 2023 · Before open | +3.9% |
| Q4 2022 | Feb 28, 2023 · Before open | +3.2% |
| Q3 2022 | Nov 7, 2022 · Before open | −11.4% |
| Q2 2022 | Aug 9, 2022 · Before open | −4.3% |
| Q1 2022 | May 9, 2022 · Before open | −6.7% |
| Q4 2021 | Feb 28, 2022 · Before open | +4.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| European Respiratory Society (ERS) Congress 2026 | Conference | 9 slides | September 2026 |
| ATS 2026 | Conference | 21 slides | May 2026 |
| FY 2025 Earnings Presentation | Earnings | 39 slides | Feb 24, 2026 |
| Investor Presentation (January 2026) | Investor deck | 27 slides | Jan 12, 2026 |
| 67th ASH Annual Meeting 2025 | Conference | 15 slides | December 2025 |
| 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress | Conference | 20 slides | May 2025 |
| Corporate Update (January 2025) | Corporate update | 39 slides | Jan 13, 2025 |
| 66th ASH Annual Meeting 2024 | Conference | 17 slides | December 2024 |
| Q3 2024 Earnings Presentation | Earnings | 38 slides | Nov 5, 2024 |
| Alpha-1 National Conference 2024 | Conference | 21 slides | Jun 8, 2024 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| J.P. Morgan Healthcare Conference January 2024 | Conference | 26 slides | Jan 8, 2024 |
| Investor Presentation (October 2023) | Investor deck | 26 slides | Oct 19, 2023 |
| Investor Presentation (January 2023) | Investor deck | 25 slides | Jan 9, 2023 |
| Corporate Update (January 2022) | Corporate update | 26 slides | Jan 10, 2022 |
| Investor Presentation (January 2021) | Investor deck | 34 slides | Jan 12, 2021 |
| Technical Presentation (December 2020) | Technical | 12 slides | December 2020 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$500M · US$28.48 a share · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Cantor (co-lead), Citigroup (co-lead), Wells Fargo Securities (co-lead) Use of proceeds: Advancing its base editing platform and programs, BEAM-101 BLA and pre-commercial work, BEAM-302 and ESCAPE trials, and general corporate purposes | Mar 10, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Feb 5, 2020.
- Price
- US$17.00 a share
- Shares offered
- 10,588,236 shares of common stock
- Offering size
- US$180 million
- Underwriters' option
- Up to 1,588,235 more shares
- Listing
- BEAM on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Jefferies, Barclays, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Feb 10, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 29, 2019 |
| Filed publicly | Sep 27, 2019 |
| Amended 4 times | Newest Feb 5, 2020 |
| Shares registered with an exchange | Jan 31, 2020 |
| Declared effective by the SEC | Feb 5, 2020 |
| Final prospectus, with the price | Feb 7, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 7, 2020 |
| EFFECT · Notice that a registration is effective | Feb 5, 2020 |
| S-1MEF · Registration of more shares for the same offering | Feb 5, 2020 |
| S-1/A · Registration statement, amended | Feb 5, 2020 |
| CERT · Exchange's certificate of listing | Feb 3, 2020 |
| CORRESP · Letter to the SEC | Feb 3, 2020 |
| CORRESP · Letter to the SEC | Feb 3, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 31, 2020 |
| S-1/A · Registration statement, amended | Jan 31, 2020 |
| CORRESP · Letter to the SEC | Jan 30, 2020 |
All 23 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jan 30, 2020 |
| S-1/A · Registration statement, amended | Jan 27, 2020 |
| CORRESP · Letter to the SEC | Jan 17, 2020 |
| S-1/A · Registration statement, amended | Jan 17, 2020 |
| UPLOAD · Letter from the SEC | Oct 7, 2019 |
| CORRESP · Letter to the SEC | Oct 2, 2019 |
| CORRESP · Letter to the SEC | Sep 27, 2019 |
| S-1 · Registration statement | Sep 27, 2019 |
| UPLOAD · Letter from the SEC | Sep 23, 2019 |
| DRS/A · Draft registration statement, amended | Sep 9, 2019 |
| DRSLTR · Letter to the SEC with a draft | Sep 6, 2019 |
| UPLOAD · Letter from the SEC | Aug 23, 2019 |
| DRS · Draft registration statement | Jul 29, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 7, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.7M | 63.5M | 377.7M | 60.9M | 51.8M | 24.0K | 18.0K | 0 | |
| Cost of revenue | 22.3M | 367.6M | 437.4M | 311.6M | 232.1M | 103.2M | 54.6M | 33.9M | 11.0K |
| Gross profit | 117.4M | -304.0M | 377.7M | -250.7M | -180.3M | -103.2M | -54.6M | -33.9M | -11.0K |
| Research and development | 409.6M | 367.6M | 437.4M | 311.6M | 387.1M | 103.2M | 54.6M | 33.9M | 5.86M |
| Selling, general and administrative | 113.8M | 111.5M | 116.8M | 87.8M | 57.2M | 29.6M | 20.6M | 11.9M | 2.02M |
| Operating income | -383.7M | -415.6M | -176.5M | -338.5M | -392.5M | -132.8M | -75.2M | -45.7M | -8.60M |
| Depreciation and amortization | 22.3M | 21.9M | 20.0M | 14.1M | 7.45M | 4.74M | 3.50M | 650.0K | 11.0K |
| EBITDA | -361.4M | -393.6M | -156.5M | -324.3M | -385.0M | -128.0M | -71.7M | -45.1M | -8.59M |
| Interest expense | 43.7M | 49.1M | 46.7M | 15.3M | 9.00K | 1.57M | 187.0K | 0 | 0 |
| Income before tax | -80.0M | -376.7M | -131.2M | -260.2M | -370.6M | -194.6M | -78.3M | -116.7M | -8.73M |
| Income tax | 0 | 39.0K | 1.37M | 3.41M | 0 | 0 | 0 | -71.0M | 500.0K |
| Net income | -80.0M | -376.7M | -132.5M | -289.1M | -370.6M | -194.6M | -78.3M | -115.3M | -8.73M |
| Earnings per share, basic | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 | -3.28 | -0.67 |
| Earnings per share, diluted | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 294.9M | 282.0M | 435.9M | 232.8M | 560.0M | 162.2M | 37.2M | 146.4M | 1.90M |
| Short-term investments | 950.3M | 568.8M | 754.0M | 845.4M | 405.7M | 137.5M | 54.6M | ||
| Receivables | 0 | 300.0M | 0 | ||||||
| Inventory | -607.4M | ||||||||
| Current assets | 1.27B | 878.1M | 1.21B | 1.09B | 1.27B | 308.3M | 94.5M | 148.3M | 2.04M |
| Property, plant and equipment | 104.5M | 111.4M | 125.0M | 115.6M | 84.3M | 38.5M | 24.3M | 16.9M | |
| Total assets | 1.48B | 1.10B | 1.46B | 1.34B | 1.47B | 451.7M | 156.1M | 167.0M | 2.40M |
| Accounts payable | 10.2M | 3.87M | 1.62M | 9.03M | 7.47M | 6.31M | 7.85M | 7.35M | 726.0K |
| Current liabilities | 96.9M | 182.1M | 205.6M | 223.6M | 213.4M | 102.3M | 29.1M | 25.6M | 6.57M |
| Long-term debt | 3.01M | 5.29M | 4.41M | ||||||
| Total debt | 293.9M | 161.4M | 172.7M | 179.0M | 147.6M | 107.6M | 31.2M | 1.01M | |
| Total liabilities | 242.8M | 370.3M | 478.4M | 608.2M | 647.7M | 206.1M | 55.2M | 33.0M | 6.58M |
| Shareholders' equity | 1.24B | 733.5M | 981.3M | 733.5M | 826.7M | 245.6M | -201.1M | 134.0M | -4.18M |
| Shares outstanding | 101.7M | 83.6M | 81.6M | 71.3M | 68.4M | 57.3M | 7.33M | 35.1M | 13.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -345.1M | -347.2M | -149.2M | 22.5M | -66.3M | -95.7M | -72.0M | -20.3M | -2.71M |
| Capital spending | -14.9M | -8.95M | -33.7M | -49.0M | -46.8M | -16.4M | -12.5M | -13.1M | -346.0K |
| Free cash flow | -360.0M | -356.2M | -182.9M | -26.4M | -113.1M | -112.1M | -84.5M | -33.4M | -3.05M |
| Cash from investing | -121.4M | 185.0M | 71.8M | -461.3M | -294.1M | -100.1M | -66.7M | -13.4M | -346.0K |
| Cash from financing | 478.0M | 7.74M | 276.4M | 111.6M | 756.1M | 322.3M | 41.3M | 179.7M | 4.98M |
| Dividends paid | -12.7M | ||||||||
| Share buybacks | 758.3M | -25.2M | |||||||
| Change in cash | 11.5M | -154.5M | 199.1M | -327.2M | 395.7M | 126.5M | -97.4M | 146.0M | 1.93M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 27, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 30, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 24, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 24, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| 8-K · Current report | Feb 12, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2025 | Acquisition or disposal | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2025 | Financing | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 18, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 18, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Apr 2, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 2, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 31, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2025 | Material contract | SEC |
| FWP · Free writing prospectus | Mar 10, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 25, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 25, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 30, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 8-K · Current report | Dec 6, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 4, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Current report | SEC |
| 8-K · Current report | Nov 5, 2024 | Current report | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 21, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 19, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 8-K · Current report | Jul 15, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 27, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 10, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
This page holds 200 of 515 filings. Open Filings
Cap table
Built by 6ix from Beam Therapeutics Inc.’s releases · as of Mar 10, 2025
- Common shares
- 103,495,644
- Fully diluted
- 103,495,644
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 103,495,644 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 103,495,644 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Nelsen Other companies: City Therapeutics, Inc. (Board Director · Since at least Oct 19, 2026); Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Lyell Immunopharma, Inc. (Director · Jun 16, 2021 – Jun 14, 2024 · Past); Revolution Healthcare Acquisition Corp (Director · Mar 17, 2021 – Mar 17, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 30, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Apr 13, 2021 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 2, 2021 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 29, 2016 – Jun 8, 2017 · Past); Bellerophon Therapeutics Inc (Director · Feb 12, 2015 – Feb 13, 2015 · Past); Juno Therapeutics Inc (Director · Dec 18, 2014 – Mar 5, 2018 · Past); Sage Therapeutics Inc (Director · Jul 17, 2014 – Nov 9, 2015 · Past); Fate Therapeutics, Inc. (Director · Sep 30, 2013 – Oct 4, 2013 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Mar 3, 2017 · Past); Kythera Biopharmaceuticals Inc (Director · Oct 10, 2012 – Aug 14, 2014 · Past); NeurogesX Inc (Director · May 1, 2007 – Jun 7, 2012 · Past); Adolor Corp (Director · May 18, 2006 – May 17, 2007 · Past) | Director · Feb 5, 2020 – Mar 31, 2021 · Past |
| John M. Maraganore Other companies: City Therapeutics, Inc. (Executive Chair · Since at least Oct 19, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Jan 29, 2026); Rapport Therapeutics, Inc. (Venture Partner, ARCH Venture Partners and Atlas Ventures · Since at least Jun 6, 2024); Kymera Therapeutics, Inc. (Director · Since at least Jan 17, 2022); Alnylam Pharmaceuticals, Inc. (Director · Since at least May 12, 2006); Instil Bio, Inc. (Director · Jun 11, 2025 – Nov 4, 2026 · Past); ProKidney Corp. (Director · Jul 11, 2022 – Jun 29, 2023 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Dec 31, 2022 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Sep 14, 2017 · Past); Regulus Therapeutics Inc (Director · Oct 4, 2012 – Oct 10, 2012 · Past) | Board Member · Since at least Nov 5, 2021 |
| Kristina Burow Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Boundless Bio, Inc. (Director · Since at least Mar 27, 2024); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 21, 2020 · Past); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past) | Director · Feb 5, 2020 – Jun 6, 2023 · Past |
| Graham Cooper Other companies: Kezar Life Sciences, Inc. (Director · Since at least Jun 20, 2018); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Applied Molecular Transport Inc (Director · Jun 4, 2020 – Jan 27, 2022 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Assembly Biosciences, Inc. (See Remarks · Mar 8, 2018 – Mar 29, 2019 · Past); Eiger Biopharmaceuticals Inc (Director · Jan 29, 2014 – Jun 4, 2015 · Past); Receptos Inc (Chief Financial Officer · May 8, 2013 – Aug 27, 2015 · Past); Geron Corporation (EVP, Bus Dev & CFO · Jan 5, 2012 – May 17, 2012 · Past); Orexigen Therapeutics Inc (CFO and Treasurer · Apr 25, 2007 – Jan 18, 2011 · Past) | Director · Since at least Feb 5, 2020 |
| Carole Ho Other companies: Eli Lilly and Company (Executive Vice President and President, Lilly Neuroscience · Since at least Dec 31, 2025); Royalty Pharma plc (Director · Since at least Jul 17, 2025); Denali Therapeutics Inc. (Chief Medical Officer · Since at least Apr 1, 2019); NGM Biopharmaceuticals Inc (Director · Jun 5, 2020 – Apr 5, 2024 · Past) | Director · Since at least Feb 5, 2020 |
| Christi Shaw Other companies: Kyverna Therapeutics, Inc. (Executive Chairperson · Since at least Sep 16, 2024); Avantor, Inc. (Director · May 16, 2019 – May 11, 2023 · Past); Eli Lilly and Company (SVP and Pres., Lilly Bio-Meds · Apr 3, 2017 – May 3, 2019 · Past) | Board Member · Since at least Dec 13, 2023 |
| Kathleen E Walsh Other companies: LifeMD, Inc. (Director · Dec 15, 2022 – Dec 15, 2022 · Past); WellCare Health Plans Inc (Director · May 23, 2018 – Jan 23, 2020 · Past); Imprivata Inc (Director · Feb 24, 2016 – Sep 16, 2016 · Past) | Director · Since at least Jan 10, 2021 |
| Sravan Emany Other companies: Kyverna Therapeutics, Inc. (Independent Director · Since at least Feb 24, 2026); Assertio Holdings, Inc. (Director · Since at least Nov 14, 2023); Ironwood Pharmaceuticals, Inc. (SVP, COO and CFO · Dec 6, 2021 – Nov 18, 2024 · Past) | Chief Financial Officer · Since at least Dec 19, 2024 |
| Chirfi Guindo Other companies: Merck & Company, Inc. (EVP, Access, Policy & Comms · Since at least Jul 1, 2022); Biogen Inc. (Head of Glob Prod Strat & Com · Nov 7, 2017 – Feb 18, 2022 · Past) | Board Member · Since at least Dec 2, 2024 |
| Terry-Ann Burrell Other companies: Rapport Therapeutics, Inc. (Director · Jun 6, 2024 – Jun 6, 2024 · Past); Recursion Pharmaceuticals, Inc. (Director · Apr 15, 2021 – Jul 1, 2024 · Past) | Chief Financial Officer · Feb 5, 2020 – Apr 26, 2024 · Past |
All 22 people
| Person | Seat |
|---|---|
| John Evans Other companies: Verve Therapeutics Inc (Director · Jun 16, 2021 – Jun 9, 2022 · Past) | Chief Executive Officer and Board Member · Since at least Feb 5, 2020 |
| Amy Simon | Chief Medical Officer · Since at least Mar 16, 2023 |
| Bethany Cavanagh | Senior Vice President of Finance, Treasurer and Principal Accounting Officer · Since at least Aug 9, 2024 |
| Christine Bellon | Chief Legal Officer · Since at least Mar 16, 2023 |
| Eric Foster | Chief Commercial Officer · Since Sep 1, 2026 |
| Giuseppe Ciaramella | President · Since at least Feb 5, 2020 |
| Gopi Shanker | Chief Scientific Officer · Since at least Jun 18, 2026 |
| Kate Walsh | Board Member · Since at least Nov 4, 2026 |
| Manmohan Singh | Chief Technology Officer · Since at least Nov 5, 2026 |
| Mark Fishman | Independent Lead Director · Since at least Feb 5, 2020 |
| Stephen C Knight | Director · Feb 5, 2020 – Feb 5, 2020 · Past |
| Susan O’Connor | Chief Human Resources Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Beam Therapeutics Inc.